Abstract
Despite being a weak point in their life cycle, transmission of Plasmodium parasites from humans to mosquitoes is an understudied field of research. Direct membrane feeding assays (DMFA) are an important tool, allowing detailed mechanistic malaria transmission studies from humans to mosquitoes. Especially for Plasmodium vivax, which cannot be cultured long-term under laboratory conditions, implementation of DMFAs requires proximity to P. vivax endemic areas. In the present study, we investigated the infectivity of symptomatic Plasmodium infections to Anopheles farauti colony mosquitoes in Papua New Guinea (PNG), a country with one of the highest rates of Plasmodium vivax in the world. A total of 182 DMFAs were performed with venous blood collected from symptomatic malaria patients positive by rapid diagnostic test (RDT). DMFAs resulted in mosquito infection in 20.9% (38/182) of cases. The parasite species in the blood feeds were determined retrospectively by expert light microscopy and quantitative real-time qPCR. Based on light microscopy, 9.2% of P. falciparum and 42% of P. vivax human infections resulted in mosquito infections. Infections containing gametocytes detected by microscopy led to mosquito infections in 58.8% of P. vivax and 8.7% of P. falciparum infections. Based on qPCR, 10% of P. falciparum and 43.6% of P. vivax lead to a successful mosquito infection. Venous blood samples from symptomatic P. vivax patients were more infectious to An. farauti mosquitoes in DMFAs compared to P. falciparum infected patients. The capacity to perform DMFAs in a high-burden P. vivax setting creates a unique opportunity to address critical gaps in our understanding of P. vivax human-tomosquito transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the Bill and Melinda Gates Foundation (OPP1034577), National Institute of Allergy and Infectious Diseases (NIAID) (5U19AI089686-03), Swiss National Science Foundation (310030_134889), and National Health and Medical Research Council (NHMRC) of Australia (GNT1127356).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received approval from two oversight bodies; 1) PNGIMR Institutional Review Board (IRB #1516) 2) PNG Medical Research Advisory Committee (MRAC #16.01)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data for the study is available for those interested
